Bristol Myers to buy MyoKardia in $13B bet on targeted drugs for the heart

Bristol Myers Squibb on Monday said it will pay $13.1 billion to acquire MyoKardia, a developer of medicines for genetic forms of heart disease.
Bristol Myers is paying $225 per share for MyoKardia, a roughly 61% premium to the biotech's $139.60 closing price on Friday. The acquisition gives the larger drugmaker rights to mavacamten, a treatment for a chronic heart condition known as obstructive hypertrophic cardiomyopathy that could be headed for a regulatory review by next year.